DNA-硫鸟嘌呤核苷酸作为硫嘌呤治疗综合生物标志物的系统评价与Meta分析
该系统评价与Meta分析评估DNA-TG作为硫嘌呤(硫鸟嘌呤、硫唑嘌呤、巯嘌呤)治疗监测标志物的证据,纳入21项研究(ALL 16项,IBD 5项)。Meta分析显示,白细胞减少患者(ALL+IBD)DNA-TG水平较无白细胞减少者平均高134.15 fmol TG/µg DNA(95%CI 83.78-184.35,P<0.00001);IBD患者中差异为161.76 fmol TG/µg DNA(95%CI 126.23-197.29,P<0.00001),而ALL患者中无显著差异。DNA-TG与TPMT、NUDT15等基因变异相关,可能优于红细胞6-TGN。
要点
- DNA-TG水平与IBD患者迟发性白细胞减少相关,推荐预测阈值320-340 fmol/µg DNA。
- DNA-TG可综合反映TPMT和NUDT15变异影响,尤其适用于NUDT15变异率高的族群。
- ALL患者中DNA-TG与白细胞减少无显著关联,但可能预测复发率。
核心结论
- DNA-TG是与治疗结局(ALL无复发生存、IBD白细胞减少风险)相关的有前景标志物,支持进一步研究。
- DNA-TG能有效识别NUDT15变异,并预测IBD患者迟发性白细胞减少,不受NUDT15变异状态影响。
研究设计与样本
- 系统评价与Meta分析,检索PubMed和Embase截至2024年4月,纳入21项测量白细胞DNA-TG水平的研究(ALL 16项,IBD 5项)。
- 使用R studio 4.1.3分析DNA-TG与6-TGN水平相关系数差异,RevMan 5.4分析白细胞减少组与无白细胞减少组DNA-TG水平差异(随机效应模型)。
- 采用Newcastle-Ottowa量表评估偏倚风险。
主要发现
- 白细胞减少患者(ALL+IBD)与无白细胞减少者DNA-TG总体平均差异为134.15 fmol TG/µg DNA(95%CI 83.78-184.35,P<0.00001;异质性卡方5.62,I²=47%)。
- IBD患者中,白细胞减少组与无白细胞减少组DNA-TG差异为161.76 fmol TG/µg DNA(95%CI 126.23-197.29,P<0.00001;异质性卡方0.20,I²=0%)。
- ALL患者中,白细胞减少组与无白细胞减少组DNA-TG差异无统计学意义(57.71 fmol TG/µg DNA,95%CI -22.93至138.35,P<0.80)。
- DNA-TG监测可能预测ALL复发率,且可能比红细胞6-TGNs更好地预测IBD患者白细胞减少。
- DNA-TG水平与TPMT、NUDT15、ITPA和MRP4等多种基因变异相关。
关键数值与推荐
- IBD患者迟发性白细胞减少的DNA-TG预测阈值建议为320-340 fmol/µg DNA。
临床怎么用
- 对于IBD患者,可考虑监测DNA-TG水平以预测迟发性白细胞减少风险,参考阈值320-340 fmol/µg DNA。
- 在NUDT15变异率较高的族群(如中国、印度、马来、日本、西班牙裔)中,DNA-TG可能比红细胞6-TGN更全面反映硫嘌呤代谢影响。
- DNA-TG监测可用于评估ALL患者复发风险,但预测白细胞减少的价值有限。
局限性
- 纳入研究数量有限(21项),ALL和IBD患者中DNA-TG与白细胞减少的关联存在异质性。
- DNA-TG检测方法(LC-MS/MS)的标准化和临床实施仍需更多研究。
- 原文未报告所纳入研究的具体样本量、各研究偏倚风险细节及DNA-TG与复发率关联的定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Thioguanine (TG), azathioprine (AZA), and mercaptopurine (MP) are thiopurine prodrugs commonly used to treat diseases, such as leukemia and inflammatory bowel disease (IBD). 6-thioguanine nucleotides (6-TGNs) have been commonly used for monitoring treatment. High levels of 6-TGNs in red blood cells (RBCs) have been associated with leukopenia, the cutoff levels that predict this side effect remain uncertain. Thiopurines are metabolized and incorporated into leukocyte DNA. Measuring levels of DNA-incorporated thioguanine (DNA-TG) may be a more suitable method for predicting clinical response and toxicities such as leukopenia. Unfortunately, most methodologies to assay 6-TGNs are unable to identify the impact of NUDT15 variants, effecting mostly ethnic populations (e.g., Chinese, Indian, Malay, Japanese, and Hispanics). DNA-TG tackles this problem by directly measuring thioguanine in the DNA, which can be influenced by both TPMT and NUDT15 variants. While RBC 6-TGN concentrations have traditionally been used to optimize thiopurine therapy due to their ease and affordability of measurement, recent developments in liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques have made measuring DNA-TG concentrations in lymphocytes accurate, reproducible, and affordable. The objective of this systematic review was to assess the current evidence of DNA-TG levels as marker for thiopurine therapy, especially with regards to NUDT15 variants. METHODS: A systematic review and meta-analysis were performed on the current evidence for DNA-TG as a marker for monitoring thiopurine therapy, including methods for measurement and the illustrative relationship between DNA-TG and various gene variants (such as TPMT, NUDT15, ITPA, NT5C2, and MRP4). PubMed and Embase were systematically searched up to April 2024 for published studies, using the keyword "DNA-TG" with MeSH terms and synonyms. The electronic search strategy was augmented by a manual examination of references cited in articles, recent reviews, editorials, and meta-analyses. A meta-analysis was performed using R studio 4.1.3. to investigate the difference between the coefficients (Fisher's z-transformed correlation coefficient) of DNA-TG and 6-TGNs levels. A meta-analysis was performed using RevMan version 5.4 to investigate the difference in DNA-TG levels between patients with or without leukopenia using randomized effect size model. The risk of bias was assessed using the Newcastle-Ottowa quality assessment scale. RESULTS: In this systematic review, 21 studies were included that measured DNA-TG levels in white blood cells for either patients with ALL (n = 16) or IBD (n = 5). In our meta-analysis, the overall mean difference between patients with leukopenia (ALL + IBD) versus no leukopenia was 134.15 fmol TG/µg DNA [95% confidence interval (CI) (83.78-184.35), P < 0.00001; heterogeneity chi squared of 5.62, I2 of 47%]. There was a significant difference in DNA-TG levels for patients with IBD with and without leukopenia [161.76 fmol TG/µg DNA; 95% CI (126.23-197.29), P < 0.00001; heterogeneity chi squared of 0.20, I2 of 0%]. No significant difference was found in DNA-TG level between patients with ALL with or without leukopenia (57.71 fmol TG/µg DNA [95% CI (- 22.93 to 138.35), P < 0.80]). DNA-TG monitoring was found to be a promising method for predicting relapse rates in patients with ALL, and DNA-TG levels are likely a better predictor for leukopenia in patients with IBD than RBC 6-TGNs levels. DNA-TG levels have been shown to correlate with various gene variants (TPMT, NUDT15, ITPA, and MRP4) in various studies, points to its potential as a more informative marker for guiding thiopurine therapy across diverse genetic backgrounds. CONCLUSIONS: This systematic review strongly supports the further investigation of DNA-TG as a marker for monitoring thiopurine therapy. Its correlation with treatment outcomes, such as relapse-free survival in ALL and the risk of leukopenia in IBD, underscores its role in enhancing personalized treatment approaches. DNA-TG effectively identifies NUDT15 variants and predicts late leukopenia in patients with IBD, regardless of their NUDT15 variant status. The recommended threshold for late leukopenia prediction in patients with IBD with DNA-TG is suggested to be between 320 and 340 fmol/µg DNA. More clinical research on DNA-TG implementation is mandatory to improve patient care and to improve inclusivity in thiopurine treatment.
引用
- Bayoumy AB, Ansari AR, Mulder CJJ, et al. Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy. Clin Pharmacokinet. 2024. PMID: 39031224. doi:10.1007/s40262-024-01393-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。